Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2013

01-10-2013 | Original Article

Elevated 18F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis

Authors: Osamu Manabe, Hiroshi Ohira, Keiichiro Yoshinaga, Takahiro Sato, Alisa Klaipetch, Noriko Oyama-Manabe, Yoichi M. Ito, Ichizo Tsujino, Masaharu Nishimura, Nagara Tamaki

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2013

Login to get access

Abstract

Purpose

Cardiac involvement in sarcoidosis is one of the leading causes of death associated with abnormalities of the conduction system. 18F-FDG PET is useful for detecting inflammatory lesions in cardiac sarcoidosis. However, the relationship between ECG abnormalities and focal 18F-FDG uptake has not been studied. The aim of this study was to evaluate the relationship between electrocardiogram (ECG) abnormalities and the location of elevated myocardial 18F-FDG uptake in patients with sarcoidosis.

Methods

Included in the study were 50 patients (56.3 ± 14.9 years old) with histologically proven sarcoidosis with suspected cardiac involvement based on ECG or echocardiography. All patients had fasted for at least 6 h and were given unfractionated heparin (50 IU/kg) intravenously to reduce the physiological 18F-FDG uptake in the myocardium. The left ventricle (LV) wall was divided into 17 segments by visual analysis. Obvious accumulation in each segment was defined as positive.

Results

Of the 50 patients, 33 showed some ECG abnormalities, including atrioventricular (AV) block in 13. Patients with abnormal ECG findings had a higher number of regions with 18F-FDG uptake than patients without ECG abnormality (3.48 ± 2.73 vs. 1.41 ± 2.09 regions, p = 0.0051). Among ECG abnormalities, the predictor for interventricular septum wall 18F-FDG involvement was AV block (p = 0.0025).

Conclusion

Patients with ECG abnormalities showed a higher number of abnormal 18F-FDG myocardial uptake regions than patients without ECG abnormalities. In particular, focal 18F-FDG uptake in the interventricular septum in cardiac sarcoidosis was associated with AV block. Therefore, determination of regional 18F-FDG distribution might contribute to patient management in cardiac sarcoidosis.
Literature
1.
2.
Rybicki BA, Major M, Popovich Jr J, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234–41.PubMedCrossRef
3.
4.
Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–11.PubMedCrossRef
5.
Blankstein R, Naya M, Osborne M, Kim C, Murthy V, Kwong R, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoid. J Am Coll Cardiol. 2012;59:E1310.CrossRef
6.
Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133:1426–35.PubMedCrossRef
7.
Valantine HA, Tazelaar HD, Macoviak J, Mullin AV, Hunt SA, Fowler MB, et al. Cardiac sarcoidosis: response to steroids and transplantation. J Heart Transplant. 1987;6:244–50.PubMed
8.
Sugishita K, Togashi Y, Aizawa A, Asakawa M, Usui S, Ito N, et al. Postpartum complete atrioventricular block due to cardiac sarcoidosis: steroid therapy without permanent pacemaker. Int Heart J. 2008;49:377–84.PubMedCrossRef
9.
Takeda N, Yokoyama I, Hiroi Y, Sakata M, Harada T, Nakamura F, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation. 2002;105:1144–5.PubMedCrossRef
10.
Miyazaki S, Funabashi N, Nagai T, Uehara M, Kataoka A, Takaoka H, et al. Cardiac sarcoidosis complicated with atrioventricular block and wall thinning, edema and fibrosis in left ventricle: confirmed recovery to normal sinus rhythm and visualization of edema improvement by administration of predonisolone. Int J Cardiol. 2011;150:e4–10.PubMedCrossRef
11.
Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2010;52:336–46.PubMedCrossRef
12.
Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythmia Electrophysiol. 2011;4:303–9.CrossRef
13.
Ohira H, Tsujino I, Yoshinaga K. 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2011;38:1773–83.PubMedCrossRef
14.
Ohira H, Tsujino I, Sato T, Yoshinaga K, Manabe O, Oyama N, et al. Early detection of cardiac sarcoid lesions with 18F-fluoro-2-deoxyglucose positron emission tomography. Intern Med. 2011;50:1207–9.PubMedCrossRef
15.
Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989–98.PubMed
16.
Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44:1030–6.PubMed
17.
Manabe O, Oyama-Manabe N, Ohira H, Tsutsui H, Tamaki N. Multimodality evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2012;19:621–4.PubMedCrossRef
18.
Bengel FM, Higuchi T, Javadi MS, Lautamaki R. Cardiac positron emission tomography. J Am Coll Cardiol. 2009;54:1–15.PubMedCrossRef
19.
Prior JO. Diabetes and vascular (18)f-fluorodeoxyglucose positron emission tomography uptake: another step toward understanding inflammation in atherosclerosis. J Am Coll Cardiol. 2012;59:2089–90.PubMedCrossRef
20.
Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging. 2010;3:623–40.PubMedCrossRef
21.
Gyorik S, Ceriani L, Menafoglio A, Gallino A, Wyttenbach R. F-FDG PET scan as follow-up tool for sarcoidosis with symptomatic cardiac conduction disturbances requiring a pacemaker. BMJ Case Rep. 2009;2009:bcr2006070805.PubMedCrossRef
22.
Hiraga H, Hiroe M, Iwai K. Guidelines for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases (in Japanese). Tokyo: The Japanese Ministry of Health and Welfare; 1993. p. 2.
23.
Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26:1538–43.PubMedCrossRef
24.
Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933–41.PubMedCrossRef
25.
American Society of Nuclear Cardiology. Updated imaging guidelines for nuclear cardiology procedures, part 1. J Nucl Cardiol. 2001;8:G5–G58.CrossRef
26.
Machac J, Bacharach SL, Bateman TM, Bax JJ, Beanlands R, Bengel F, et al. Positron emission tomography myocardial perfusion and glucose metabolism imaging. J Nucl Cardiol. 2006;13:e121–51.PubMedCrossRef
27.
Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8.PubMedCrossRef
28.
Laffon E, Adhoute X, de Clermont H, Marthan R. Is liver SUV stable over time in 18F-FDG PET imaging? J Nucl Med Technol. 2011;39:258–63.PubMedCrossRef
29.
Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784–8.PubMed
30.
Das CJ, Makharia GK, Kumar R, Tiwari RP, Sharma R, Malhotra A. PET/CT colonography: a novel non-invasive technique for assessment of extent and activity of ulcerative colitis. Eur J Nucl Med Mol Imaging. 2010;37:714–21.PubMedCrossRef
31.
Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A dose–response study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol. 1979;7:531–3.PubMedCrossRef
32.
Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969–77.PubMedCrossRef
33.
Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2010;3:1219–28.PubMedCrossRef
34.
35.
Lie JT, Hunt D, Valentine PA. Sudden death from cardiac sarcoidosis with involvement of conduction system. Am J Med Sci. 1974;267:123–8.PubMedCrossRef
36.
Roberts WC, McAllister Jr HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86–108.PubMedCrossRef
37.
38.
Nelson JE, Kirschner PA, Teirstein AS. Sarcoidosis presenting as heart disease. Sarcoidosis Vasculitis Diffuse Lung Dis. 1996;13:178–82.
39.
Kim JS, Judson MA, Donnino R, Gold M, Cooper Jr LT, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J. 2009;157:9–21.PubMedCrossRef
40.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010. 33 Suppl 1:S62–69.CrossRef
41.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.PubMedCrossRef
42.
Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart. 2011;97:2078–87.PubMedCrossRef
43.
Epstein AE, DiMarco JP, Ellenbogen KA, Estes 3rd NA, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350–408.PubMedCrossRef
44.
Koiwa H, Tsujino I, Ohira H, Yoshinaga K, Otsuka N, Nishimura M. Images in cardiovascular medicine: imaging of cardiac sarcoid lesions using fasting cardiac 18F-fluorodeoxyglucose positron emission tomography: an autopsy case. Circulation. 2010;122:535–6.PubMedCrossRef
Metadata
Title
Elevated 18F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis
Authors
Osamu Manabe
Hiroshi Ohira
Keiichiro Yoshinaga
Takahiro Sato
Alisa Klaipetch
Noriko Oyama-Manabe
Yoichi M. Ito
Ichizo Tsujino
Masaharu Nishimura
Nagara Tamaki
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2460-5

Other articles of this Issue 10/2013

European Journal of Nuclear Medicine and Molecular Imaging 10/2013 Go to the issue

Letter to the Editor

Gratifying clinical experience with an indigenously formulated single-vial lyophilized HYNIC-TOC kit at the radiopharmaceutical division of BARC: a pivotal boost for building up a peptide receptor radionuclide therapy programme in an Indian setting

Original Article

In vivo bioluminescence reporter gene imaging for the activation of neuronal differentiation induced by the neuronal activator neurogenin 1 (Ngn1) in neuronal precursor cells

Original Article

PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinoma

Original Article

Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients

Original Article

Observer reproducibility of results from a low-dose 123I-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failure

Image of the Month

PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer